Led by Dr. Kylie Wagstaff and team, Monash University, in collaboration with the Doherty Institute, triggered global interest in ivermectin, an FDA-approved marketed anti-parasitic drug, as a potential antiviral for the COVID-19 causative virus, SARS-CoV-2. The team’s preliminary lab work demonstrated that ivermectin reduces viral replication in vitro and there represents potential to reduce viral load. The Australian-based research served as a catalyst for researchers from Asia and Europe to North America and South America. Controversially, Ivermectin has even been approved as a treatment for patients with mild COVID-19 infections by Peru and possibly regional government in Bolivia. At least 18 ivermectin-based clinical trials have commenced in four different continents. Now with recent funding from Helmsley Trust and funds from the Australian government, Monash University investigators embark on a research mission to further evaluate ivermectin as well as a few other investigational approaches, in their ongoing and relentless March down in Melbourne to discovery new breakthrough therapies to address COVID-19.
As the university recently reported, Federal Hea...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).